Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBITDA (2016 - 2025)

Historic EBITDA for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $62.1 million.

  • Collegium Pharmaceutical's EBITDA rose 7821.12% to $62.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.0 million, marking a year-over-year decrease of 1885.65%. This contributed to the annual value of $169.9 million for FY2024, which is 175.73% up from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's EBITDA is $62.1 million, which was up 7821.12% from $35.1 million recorded in Q2 2025.
  • Collegium Pharmaceutical's EBITDA's 5-year high stood at $62.1 million during Q3 2025, with a 5-year trough of -$34.1 million in Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median EBITDA value was $24.6 million (recorded in 2023), while the average stood at $26.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 32754.07% in 2021, then surged by 42469.17% in 2023.
  • Collegium Pharmaceutical's EBITDA (Quarter) stood at -$34.1 million in 2021, then soared by 134.46% to $11.8 million in 2022, then skyrocketed by 424.69% to $61.7 million in 2023, then plummeted by 38.22% to $38.1 million in 2024, then soared by 62.91% to $62.1 million in 2025.
  • Its EBITDA was $62.1 million in Q3 2025, compared to $35.1 million in Q2 2025 and $21.7 million in Q1 2025.